Cargando…
Efficacy and Safety of PD-1/PD-L1 Inhibitor as Single-Agent Immunotherapy in Endometrial Cancer: A Systematic Review and Meta-Analysis
SIMPLE SUMMARY: The programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) pathway controls the induction and maintenance of immune tolerance within the tumor microenvironment. Hence, immunotherapy is an exciting approach, and tremendous strides have recently been made in our...
Autores principales: | Mamat @ Yusof, Mohd Nazzary, Chew, Kah Teik, Hafizz, Abdul Muzhill Hannaan Abdul, Abd Azman, Siti Hajar, Ab Razak, Wira Sofran, Hamizan, Muhammad Rafi’uddin, Kampan, Nirmala Chandralega, Shafiee, Mohamad Nasir |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10452317/ https://www.ncbi.nlm.nih.gov/pubmed/37627060 http://dx.doi.org/10.3390/cancers15164032 |
Ejemplares similares
-
Expression of PD-1 and PD-L1 in Endometrial Cancer: Molecular and Clinical Significance
por: Mamat @ Yusof, Mohd Nazzary, et al.
Publicado: (2023) -
Sexual functioning and marital satisfaction among endometriosis patients in Malaysia: a cross-sectional study
por: Rao, Sharvina Ramesh, et al.
Publicado: (2023) -
PD-L1 Expression in Endometrial Cancer and Its Association with Clinicopathological Features: A Systematic Review and Meta-Analysis
por: Mamat @ Yusof, Mohd Nazzary, et al.
Publicado: (2022) -
Where are we going with sentinel nodes mapping in ovarian cancer?
por: Kampan, Nirmala Chandralega, et al.
Publicado: (2022) -
New Predictive Biomarkers for Ovarian Cancer
por: Atallah, Ghofraan Abdulsalam, et al.
Publicado: (2021)